Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$26350.00
-350.00 (-1.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $17.6B · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$154.9B
P/E
5.6x
↓EV/EBITDA
2.6x
↓ROE
9.2%
↑Gross Margin
31.1%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.2%
FCF CAGR
-71.3%
FCF margin
0.2%
FCF / Net income
0.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $208.61B · net income $27.64B · FCF $481.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $208.61B | $208.61B | $204.19B | $195.91B | $184.27B |
| Net Income | $27.64B | $27.64B | $33.76B | $28.43B | $24.96B |
| EBITDA | $42.38B | $42.38B | $49.61B | $45.45B | $43.25B |
| EPS | 4701.00 | 4701.00 | 5741.00 | 4834.00 | 4171.00 |
| Gross Margin | 31.1% | 31.1% | 34.2% | 33.6% | 32.7% |
| Operating Margin | 14.9% | 14.9% | 18.6% | 18.3% | 17.9% |
| Net Margin | 13.3% | 13.3% | 16.5% | 14.5% | 13.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | — | 0.03 |
| Current Ratio | 3.61 | 3.61 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $481.5M | $481.5M | $19.84B | $17.58B | $20.38B |
| Returns | |||||
| ROE | 9.2% | 9.2% | 12.2% | 11.5% | 11.1% |
| Valuation | |||||
| P/E | 5.61 | 5.61 | 4.55 | 5.78 | 7.22 |
| EV/EBITDA | 2.62 | 2.62 | 1.86 | 1.38 | 2.21 |
| P/B | 0.52 | 0.52 | 0.56 | 0.66 | 0.80 |
| Growth & Yield | |||||
| Revenue Growth | 2.2% | 2.2% | 4.2% | 6.3% | — |
| EPS Growth | -18.1% | -18.1% | 18.8% | 15.9% | — |
| Dividend Yield | 3.8% | 3.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-20.8%
EPS terminal req.
$2338.12
Spread vs growth
2.7%
5Y implied EPS CAGR
-9.7%
EPS terminal req.
$2829.13
Spread vs growth
-8.5%
10Y implied EPS CAGR
-0.3%
EPS terminal req.
$4556.34
Spread vs growth
-17.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.3%
Start / end P/E
4.8x → 5.6x
EPS bridge
5741.00 → 4701.00
Residual
-3.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.